High-dose chemotherapy with hematopoietic rescue in breast cancer: From theory to practice

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Bezwoda, W R ^a  

^a UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Breast cancer; High dose chemotherapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GLYCOPROTEIN P; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; PREDNISONE; PROCARBAZINE; THIOTEPA; VINCRISTINE;

BREAST CANCER; CHEMOTHERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION; HUMAN; MORTALITY; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; THEORY;

EID: 0030875042     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051067     Document Type: Conference Paper

References (33)

1. Antman K, Ayash L, Ehas AD, Wheeler C, Tepler I, Hunt M, Frei E III (1992) A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol 10:102
2. Bastholt L, Dalmark M, Gjedde S (1992) Epirubicin at four different dose levels in metastatic breast cancer. A randomised trial. Proc Am Soc Clin Oncol 11:56A
3. Bezwoda WR, Dansey R, Seymour L (1989) First line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 46:208
4. Bezwoda WR, Seymour L, Ariad S (1991) High dose etoposide in treatment of metastatic breast cancer. Oncology 183:104
5. Bezwoda WR, Seymour L, Dansey RD (1995) High dose chemotherapy with hematopoetic rescue as primary treatment for metastatic breast cancer: a randomised trial. J Clin Oncol 13:2483
6. Bonadonna G, Valagusia P, Santoro A (1986) Alternating non-cross-resistant combination chemotherapy or MOPP in stage I Hodgkin's disease. Ann Intern Med 104:739
7. Bourgeois N, Gruia G, Dieras V, Kalla S, Giaccetti S, Cvitkovic E, Aussel JP, Azli N, Riva A, Pouillart P, Misset JL (1996) Docetaxel (D) in combination with doxorubicin (Dx) as 1st line CT of metastatic breast cancer (MBC): a phase I dose finding study (abstract). Proc Am Soc Clin Oncol 15:148
8. Carter CL, Allen C, Heuson DC (1989) Relationship of tumor size, lymph node status, and survival in 24, 740 breast cancer cases. Cancer 63:181
9. Dansey RD, Hessel PA, Browde S, Lange M, Derman D, Nissenbaum N, Bezwoda WR (1988) Lack of a significant independent effect of race on breast cancer survival. Cancer 61:1908
10. Dunphy FR, Spitzer G, Buzdar AU (1990) Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207
11. Early Breast Cancer Trialists Collaborative Group (1990) Treatment of early breast cancer, vol 1. Worldwide evidence 1985-1990. Oxford University, Oxford, p 50
12. Frassinetti GL, Zoli W, Tienghi A, Ravaioli A, Milandri C, Gentile C, Onetto N, Amadori D (1996) Phase I/II study of sequential combination of placlitaxel and doxorubicin in the treatment of advanced breast cancer (ABC) (abstract). Proc Am Soc Clin Oncol 15:109
13. Geissler K (1996) Stem cell mobilisation. Bone Marrow Transplant 17[Suppl 1]:244
14. Gilewsky T, Norton L (1995) Cytokinetics and neoplasia. In: Mendelsohn J, Howley P, Israel MA, Liotta LA (eds). The molecular basis of cancer. Saunders, Philadelphia, p 143
15. a, TXL) with blood progenitor cell support for the treatment of metastatic breast cancer (abstract). Proc Am Soc Clin Oncol 15:137
16. Goldie JH, Coldman AJ (1986) Application of theoretical models to chemotherapy protocol design. Cancer Treat Rep 70:127
17. Hryniuk W, Levine MN (1986) Analysis of dose intensity for adjuvant chemotherapy trials in Stage II breast cancer. J Clin Oncol 4:1162
18. Jones RB, Shpall EJ, Ross M, Bast R, Affronti M, Peters WP (1990) AFM induction chemotherapy followed by intensive alkylating agent consolidation with autologous bone marrow support (ABMS) for advanced breast cancer: current results (abstract). Proc Am Soc Clin Oncol 9:9
19. Kennedy MJ, Beveridge RA, Rowley SD, Jones RJ (1991) High dose chemotherapy with reinfusion of purged autologous bone marrow following dose intensive induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 83:920
20. Livingston R, Collins C, Williams M, Thompson T, Rivkin S (1994) Determinants of outcome after consolidation for stage IV breast cancer with cyclophosphamide, etoposide and cisplatin (CEP) (abstract). Proc Am Soc Clin Oncol 11:35
21. Mariani MP, Bosi A, Capovale R, Guidi S, Ieri A, Linari S, Lombardini L, Saccavili R, Vannuchi AM, Rossi Ferrini P (1996) Detection of occult breast cancer by RT-PCR in BM and PB progenitor cells mobilised with G-CSF alone. Bone Marrow Transplant 17[Suppl 1]:380
22. Nemoto T, Vana J, Bedwani RN (1980) Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 45:2917
23. NIH (1990) Consensus development conference on early breast cancer, June 18-21, NIH, Bethesda, Maryland
24. Norton L (1985) Implicatins of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231
25. Norton L, Simon R (1977) Tumour size, sensitivity to chemotherapy, and the design of treatment schedules. Cancer Treat Rep 61:1307
26. Norton L, Simon R. (1980) Growth curve of an experimental solid tumour following radiotherapy. J Natl Cancer Inst 58:1735
27. Peters WP, Jones RB, Vredenburgh J, Shpall FJ, Hussein A, Elkorily M, Rubin P, Ross M, Berry D (1996) A large prospective randomized trial of high dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) (abstract). Proc Am Soc Clin Oncol 15:121
28. Pozza F, Bevilacqua P, Cazavillan S, Meli S, Gasparini G (1993) P-glycoprotein expression (PGE) predicts chemoresistance (CR) in advanced breast cancer (ABC) (abstract). Proc Am Soc Clin Oncol 12:65
29. Seymour L, Bezwoda WR, Dansey RD (1995) P-glycoprotein immunostaining correlates with ER and with high Ki 67 expression but fails to predict for anthracycline resistance in patients with advanced breast cancer. Breast Cancer Res Treat 36:61
30. Skipper HE, Schabel FM Jr, Wilcox WS (1964) Experimental evaluation of potential anticancer agent XIII. On the criteria and kinetics associated with "curability" of experimental leukemia. Cancer Chemother Rep 35:1
31. Tannock IF, Boyd NF, De Boer G (1988) A randomised clinical trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for metastatic breast cancer. A randomised trial. J Clin Oncol 6:1377
32. Williams SF, Gilewski T, Nick R, Bitran JD (1992) High dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: follow up report. J Clin Oncol 10:1743
33. Wood WC, Budman DR, Korzun AH (1994) Dose and dose intensity trial of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253